Andrew sfekas bodog sportsbook review

Senior Manager

Contact

  • Washington

Education

Andrew Sfekas analyzes complex antitrust and competition matters. Dr. Sfekas has extensive experience with mergers in a variety of industries, and with antitrust issues arising in healthcare and the life sciences. He manages teams to support experts and attorneys across all phases of commercial litigation and regulatory investigations.

Mergers and acquisitions

Dr. Sfekas consults on a range of bodog sportsbook review and acquisition matters. His expertise includes early evaluation, engagement with antitrust agencies, second requests, preparation of reports following complaints, and trials. He has worked on horizontal and vertical transactions. Dr. Sfekas has addressed M&A issues in agriculture, healthcare, health insurance, information technology, manufacturing, streaming media, and retail banking, among others. His work has included the Second Request production of large and complex databases.

Antitrust in healthcare and life sciences

Dr. Sfekas has expertise in complex antitrust cases involving healthcare providers, health insurers, and pharmaceutical manufacturers. In these contexts, he has supported experts in matters related to allegations of vertical restraints and anticompetitive pricing practices, including liability and damages assessments. As part of this work, he has led teams in analyzing large medical claims databases.

Professional Affiliations
Article

Expanding the Economic Analysis in Banking bodog sportsbook review Review

Case

First Advantage/Sterling Check

Case

Alaska Airlines/Hawaiian Airlines bodog sportsbook review

Article

Assessing bodog sportsbook review Guideline Feedback With Machine Learning

Press Release

Cornerstone Research Staff and Affiliated Experts Submit Comments on the Joint FTC-DOJ Draft bodog sportsbook review Guidelines

Case

United States et al. v. UnitedHealth Group Incorporated et al.

Press Release

Cornerstone Research Named in GCR 2023 Matter of the Year

Article

Public’s M&A Comments Hold Clues for Agency Guidelines